RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Regulation FD Disclosure

RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

Beginning on and after November 12, 2020, RespireRx Pharmaceuticals Inc. (the “Company”) will participate in meetings with third parties in which a corporate slide presentation will be presented. The presentation includes certain forward-looking information. A copy of the presentation materials is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Beginning on and after November 12, 2020, the Company will provide by email and may make available on its website or on social media, a short summary of the Company. The summary includes certain forward-looking information. A copy of the presentation materials is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01 and the documents attached as Exhibit 99.1 and 99.2 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

99.1 RespireRx Pharmaceuticals Inc. Corporate Presentation
99.2 RespireRx Pharmaceuticals Inc. Summary


RespireRx Pharmaceuticals Inc. Exhibit

To view the full exhibit click here

Story continues below

About RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI)

RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is focused on the clinical development in the areas of respiratory disorders, including respiratory depression and sleep apnea. It is engaged in research and clinical development of a class of compounds referred to as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. Its dronabinol is indicated for the treatment of sleep-related breathing disorders, including sleep apnea.

An ad to help with our costs